D-Index & Metrics Best Publications

Guillermo Garcia-Manero

The University of Texas MD Anderson Cancer Center
United States

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name Citations Publications World Ranking National Ranking

Medicine D-index 140 Citations 79,846 1,934 World Ranking 927 National Ranking 553

Overview

What is he best known for?

The fields of study he is best known for:

Internal medicine
Cancer
Gene

Internal medicine, Leukemia, Gastroenterology, Surgery and Myeloid leukemia are his primary areas of study. His Internal medicine research integrates issues from Immunology and Oncology. His work in Oncology addresses subjects such as Survival analysis, which are connected to disciplines such as Salvage therapy.

He has researched Leukemia in several fields, including Myeloid and Pharmacology. His work deals with themes such as Cytarabine, Phases of clinical research, Blastic Phase and Survival rate, which intersect with Gastroenterology. His Myeloid leukemia study combines topics from a wide range of disciplines, such as Mutation, Fms-Like Tyrosine Kinase 3 and Young adult.

His most cited work include:

New Comprehensive Cytogenetic Scoring System for Primary Myelodysplastic Syndromes (MDS) and Oligoblastic Acute Myeloid Leukemia After MDS Derived From an International Database Merge (440 citations)
Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents (380 citations)
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes (329 citations)

What are the main themes of his work throughout his whole career to date?

Guillermo Garcia-Manero mainly investigates Internal medicine, Oncology, Myeloid leukemia, Gastroenterology and Myelodysplastic syndromes. His Internal medicine research is multidisciplinary, incorporating perspectives in Surgery and Decitabine. Guillermo Garcia-Manero has included themes like Azacitidine, Cancer, Immunology and Transplantation in his Oncology study.

His work carried out in the field of Myeloid leukemia brings together such families of science as Tyrosine kinase and Bone marrow. The study incorporates disciplines such as Refractory, Imatinib mesylate, Vincristine, Adverse effect and Neutropenia in addition to Gastroenterology. The various areas that Guillermo Garcia-Manero examines in his Leukemia study include Myeloid and Pharmacology.

He most often published in these fields:

Internal medicine (73.03%)
Oncology (37.10%)
Myeloid leukemia (25.74%)

What were the highlights of his more recent work (between 2018-2021)?

Internal medicine (73.03%)
Oncology (37.10%)
Myeloid leukemia (25.74%)

In recent papers he was focusing on the following fields of study:

His primary areas of study are Internal medicine, Oncology, Myeloid leukemia, Cancer research and In patient. His study in Internal medicine is interdisciplinary in nature, drawing from both Gastroenterology and Azacitidine. His studies in Oncology integrate themes in fields like Cytarabine, Decitabine, Venetoclax, Blinatumomab and Transplantation.

The Myeloid leukemia study combines topics in areas such as Hematopoietic stem cell transplantation, Chemotherapy regimen, Myeloid, Bone marrow and Cohort. His Myelodysplastic syndromes research includes elements of Lower risk, Clinical trial and Anemia. His research is interdisciplinary, bridging the disciplines of Cancer and Leukemia.

Between 2018 and 2021, his most popular works were:

Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study. (140 citations)
The distribution of T‐cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia (82 citations)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups (64 citations)

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Guidelines for the use and interpretation of assays for monitoring autophagy

Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham.
Autophagy (2012)

8302 Citations

Revised International Prognostic Scoring System for Myelodysplastic Syndromes

Peter L. Greenberg;Heinz Tuechler;Julie Schanz;Guillermo Sanz.
Blood (2012)

2683 Citations

Clinical effect of point mutations in myelodysplastic syndromes.

Rafael Bejar;Kristen Stevenson;Omar Abdel-Wahab;Naomi Galili.
The New England Journal of Medicine (2011)

1683 Citations

Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.

Jean Pierre J. Issa;Guillermo Garcia-Manero;Francis J. Giles;Rajan Mannari.
Blood (2004)

976 Citations

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia

Hagop Kantarjian;Yasuhiro Oki;Guillermo Garcia-Manero;Xuelin Huang.
Blood (2007)

927 Citations

Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

Omar Abdel-Wahab;Ann Mullally;Cyrus Hedvat;Guillermo Garcia-Manero.
Blood (2009)

779 Citations

Genetic Alterations Activating Kinase and Cytokine Receptor Signaling in High-Risk Acute Lymphoblastic Leukemia

Kathryn G. Roberts;Ryan D. Morin;Jinghui Zhang;Martin Hirst.
Cancer Cell (2012)

752 Citations

Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

Deborah A. Thomas;Stefan Faderl;Jorge Cortes;Susan O'Brien.
Blood (2004)

716 Citations

Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl.
Journal of Clinical Oncology (2005)

691 Citations

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

Deborah A. Thomas;Stefan Faderl;Susan O'Brien;Carlos Bueso-Ramos.
Cancer (2006)

647 Citations

If you think any of the details on this page are incorrect, let us know.

Frequent Co-Authors

External Links

Personal Website for Guillermo Garcia-Manero